Allogene Therapeutics (ALLO)Officer sold ~$22K

~$22K

Approx. value · 9,586 sh @ $2.31

125K

Holds after · shares reported

Traded

Apr 21, 2026

Filed

Apr 23, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Mar 2, 2026InsiderOfficer sold ~$19K of ALLO shares in the open market
2. Mar 12, 2026Company filing · Form 8-K · ResultsReported its results
3. Mar 16, 2026Insider · 2 peopleInsiders: 2 sales (~$130K)
4. Mar 31, 2026InsiderOfficer sold ~$7.2K of ALLO shares in the open market
5. Apr 21, 2026 · this disclosureInsiderOfficer sold ~$22K of ALLO shares in the open market

What came next

1. May 12, 2026Company filing · Form 8-K · Material agreement, Agreement endedSigned an important agreement, and ended an important agreement (and 1 more item)
2. May 28, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On May 28, 2026, the Board of Directors (the “Board”) of Allogene Therapeutics, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, approved the appointment of Zachary Roberts, M.D., Ph.D. as the Company’s President and Chief Executive Officer, replacing David Chang, M.D., Ph.D. in such capacities.”
3. Aug 12, 2026Company filing · Form 8-K · ResultsReported its results

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Allogene Therapeutics

For Allogene Therapeutics, OQRO holds 1 insider filing (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ALLO page.

Other recent filings by Annie Yoshiyama, SVP, Finance

• SEC Form 4 at Allogene Therapeutics (ALLO)Feb 4, 2026
• SEC Form 4 at Allogene Therapeutics (ALLO)Apr 23, 2025

The full history of Annie Yoshiyama, SVP, Finance is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Allogene Therapeutics

• SEC Form 4Aug 25, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 4Apr 2, 2026
• SEC Form 4Mar 18, 2026
• SEC Form 4Mar 18, 2026
• SEC Form 4Mar 4, 2026

Everything OQRO holds on this company is on its ALLO page.